About Occludin
Occludin (OCLN) is a protein
from Homo sapiens identified by UniProt accession
Q16625, 522 residues long.
MolForge cross-references it against 0 known binders and
210 disease associations.
Target properties
| Protein name | Occludin |
| UniProt accession | Q16625 |
| Gene | OCLN |
| Organism | Homo sapiens |
| Length | 522 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (210)
Diseases linked to this target (Open Targets).
- Congenital intrauterine infection-like syndrome · score 0.74
- pseudo-TORCH syndrome · score 0.55
- neurodegenerative disease · score 0.34
- serum gamma-glutamyl transferase measurement · score 0.32
- total blood protein measurement · score 0.29
- Global developmental delay · score 0.26
- Primary microcephaly · score 0.26
- Cerebral calcification · score 0.26
- glioblastoma multiforme · score 0.23
- genetic disorder · score 0.19
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q16625-F1 | alphafold | PREDICTED | 65.57 | — |
Amino-acid sequence (522 residues)
MSSRPLESPP PYRPDEFKPN HYAPSNDIYG GEMHVRPMLS QPAYSFYPED EILHFYKWTS PPGVIRILSM LIIVMCIAIF ACVASTLAWD RGYGTSLLGG SVGYPYGGSG FGSYGSGYGY GYGYGYGYGG YTDPRAAKGF MLAMAAFCFI AALVIFVTSV IRSEMSRTRR YYLSVIIVSA ILGIMVFIAT IVYIMGVNPT AQSSGSLYGS QIYALCNQFY TPAATGLYVD QYLYHYCVVD PQEAIAIVLG FMIIVAFALI IFFAVKTRRK MDRYDKSNIL WDKEHIYDEQ PPNVEEWVKN VSAGTQDVPS PPSDYVERVD SPMAYSSNGK VNDKRFYPES SYKSTPVPEV VQELPLTSPV DDFRQPRYSS GGNFETPSKR APAKGRAGRS KRTEQDHYET DYTTGGESCD ELEEDWIREY PPITSDQQRQ LYKRNFDTGL QEYKSLQSEL DEINKELSRL DKELDDYREE SEEYMAAADE YNRLKQVKGS ADYKSKKNHC KQLKSKLSHI KKMVGDYDRQ KT
Explore Occludin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets